Jun 12, 2020
FDA Approves Drug to Treat Infants and Children with HIV
May 22, 2020
Global Antiretroviral Therapy Market (NRTI, NNRTI, Protease Inhibitors & Integrase Inhibitors): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)
Aug 22, 2019
Janssen Reports Positive Top-line Phase 3 Study Results of Investigational, Long-acting Injectable HIV Treatment Regimen Administered Every Two Months
Aug 14, 2019
Non-Invasive Cellulite Treatments and Devices Dominating Billion Dollar Market
Jul 30, 2019
Five Years on, 3.9 Million People in the Developing World Have Access to HIV Treatment Dolutegravir, Thanks to Access-oriented Voluntary Licensing Agreements
Apr 29, 2019
Janssen Announces Submission of New Drug Application to U.S. FDA For the First Monthly, Injectable, Two-Drug Regimen of Rilpivirine and Cabotegravir for Treatment of HIV
Apr 17, 2019
Global Antiretroviral Market is projected to display a robust growth represented by a CAGR of 4.70% during 2018 - 2023
Apr 08, 2019
FDA approves first two-drug complete regimen for HIV-infected patients who have never received antiretroviral treatment
Nov 15, 2018
Global HIV Diagnostics and Therapeutics Markets Report 2018-2023 Featuring Abbott Laboratories, Bio-Rad Laboratories, Cipla, GSK, Merck & Co., Siemens Healthineers and Thermo Fisher Scientific
Oct 03, 2018
Hong Kong Department of Health Approves Biktarvy(R) (bictegravir, emtricitabine, tenofovir alafenamide)
Feb 20, 2018
Mylan Receives Tentative Approval for Combination HIV Treatment DTG/FTC/TAF Under FDA's PEPFAR Program
Dec 19, 2017
$179.9 Billion Enzyme Inhibitors Markets, 2022
Nov 21, 2017
Juluca® (dolutegravir and rilpivirine) approved in US as first 2-drug regimen, once-daily, single pill - a complete regimen for the maintenance treatment of virologically suppressed HIV-1 infection
Nov 21, 2017
FDA approves first two-drug regimen for certain patients with HIV
Oct 04, 2017
The Medicines Patent Pool and Gilead Sciences Sign Licence for Bictegravir
Sep 12, 2017
Now Available in Canada: ISENTRESS® HD (raltegravir), a New Once-Daily Option, in Combination with Other Antiretroviral Agents, for the Treatment of HIV-1 Infection in Appropriate Patients
Jul 25, 2017
ViiV Healthcare Announces Superior Efficacy of Dolutegravir Versus Lopinavir/Ritonavir in Second-line HIV Treatment in Resource-limited Settings
Jun 01, 2017
Janssen Announces Submissions in Europe and US for Single-Tablet Regimen of Dolutegravir plus Rilpivirine - the First Two-Drug HIV Maintenance Treatment